You are here

  • Home
  • Archive
  • Volume 79, Issue 11
  • Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Article metrics

Article menu

Download PDFPDF

XML
Systemic sclerosis
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

 

Online download statistics by month:

Online download statistics by month: August 2020 to July 2022

AbstractFullPdf
Aug 2020816782399
Sep 2020437436221
Oct 202011761173359
Nov 2020493482228
Dec 2020265259125
Jan 2021239227127
Feb 202116115266
Mar 2021151147101
Apr 202116716470
May 202112010973
Jun 202112412059
Jul 202112011561
Aug 202114013769
Sep 202119418682
Oct 202114313681
Nov 2021155140100
Dec 2021939081
Jan 2022959853
Feb 2022898453
Mar 202215415897
Apr 202211010559
May 202217118162
Jun 202216314860
Jul 2022949138
Total587057202724